Lycia Therapeutics
Lilly-backed Lycia Therapeutics Secures $106M for Clinical Trials on Lysosomal Protein Degraders
Lycia Therapeutics, Eli Lilly, lysosomal protein degraders, clinical trials, funding, biotechnology, drug development
Actionable Insights Powered by AI
Lycia Therapeutics, Eli Lilly, lysosomal protein degraders, clinical trials, funding, biotechnology, drug development